scholarly journals A Novel c-Mesenchymal-Epithelial Transition Factor Intergenic Fusion Response to Crizotinib in a Chinese Patient With Lung Adenocarcinoma: A Case Report

2021 ◽  
Vol 11 ◽  
Author(s):  
Hongge Liang ◽  
Dexun Zhou ◽  
Lin Dai ◽  
Moqin Zhang ◽  
Zhancheng Gao ◽  
...  
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease ◽  
Lower Lobe ◽  
Tyrosine Kinase Receptor ◽  
Carcinogenic Activity ◽  
First Case ◽  
Mesenchymal Epithelial Transition Factor ◽  
Factor C ◽  
Mesenchymal Epithelial Transition

BackgroundThe c-mesenchymal–epithelial transition factor (C-MET) is an oncogene encoding a tyrosine kinase receptor that plays an important role in tumor growth and metastasis. The National Comprehensive Cancer Network (NCCN) guidelines have approved carbatinib/crizotinib for advanced non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping.MethodsIn June 2020, the Department of Respiratory and Critical Care Medicine of Peking University People’s Hospital admitted a 72-year-old male patient with lung adenocarcinoma (LADC) with a history of interstitial lung disease secondary to antineutrophil cytoplasmic antibody-associated vasculitis. Genetic examination by next-generation sequencing showed an intergenic fusion of MET, and crizotinib was administered on August 14, 2020. Follow-up showed that tumor volume was significantly reduced. However, crizotinib was discontinued in November 2020 because of the patient’s worsening interstitial lung disease, and CT scans showed continued partial response (PR) for 5 months. In April 2021, right lower lobe mass progressed, and disease progression was considered.ConclusionThis was the first case of a patient with LADC with MET intergenic fusion who significantly benefited from crizotinib. Even after crizotinib was discontinued for 5 months, the patient continued exhibiting PR, suggesting that MET intergenic fusion may have carcinogenic activity in LADC and was sensitive to crizotinib.

scholarly journals Evaluation of poor prognostic factors of respiratory related death in microscopic polyangiitis complicated by interstitial lung disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Shogo Matsuda ◽  
Takuya Kotani ◽  
Takayasu Suzuka ◽  
Takao Kiboshi ◽  
Keisuke Fukui ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Clinical Laboratory ◽  
Microscopic Polyangiitis ◽  
Survival Rates ◽  
Lower Lobe ◽  
Left Lower Lobe ◽  
Fibrosis Score ◽  
High Resolution Computed Tomography

AbstractThe prognosis of microscopic polyangiitis (MPA) with interstitial lung disease (ILD) is significantly worse than that of MPA without ILD. However, the clinical characteristics in MPA-ILD, especially poor prognostic factors, are not elucidated. We evaluated demographic, clinical, laboratory, and radiological findings, treatments, and outcomes of 80 patients with MPA, and investigated prognostic factors of respiratory-related death in patients with myeloperoxidase (MPO)-anti-neutrophil cytoplasmic antibody (ANCA) positive MPA-ILD. Ground-glass opacity and fibrosis were evaluated as scores on high-resolution computed tomography (HRCT). The presence of ILD was consistent with a high risk of respiratory-related death (hazard ratio, 4.8; P = 0.04). Multivariable logistic regression analyses using propensity scoring showed right or left lower lobe fibrosis score to be significantly associated with respiratory-related death (P = 0.0005 and 0.0045, respectively). A right or left lower lobe fibrosis score ≥ 2, indicating the presence of honeycombing at 1 cm above the diaphragm, was determined to be the best cut-off value indicating a poor prognosis. The 5-year survival rate was significantly lower in patients with right or left lower lobe fibrosis score ≥ 2 (survival rates: 37% and 19%, respectively) than those with a score < 2 (71% and 68%, respectively) (P = 0.002 and 0.0007, respectively). These findings suggest that the presence of honeycomb lesions in bilateral lower lobes on chest HRCT was associated with respiratory-related death in patients with MPO-ANCA positive MPA-ILD.

scholarly journals Clinical significance of lower-lobe interstitial lung disease on high-resolution computed tomography in patients with idiopathic pleuroparenchymal fibroelastosis

2019 ◽  
Vol 154 ◽  
pp. 122-126 ◽  
Author(s):  
Masato Kono ◽  
Yuiko Fujita ◽  
Kenichiro Takeda ◽  
Koichi Miyashita ◽  
Akari Tsutsumi ◽  
...  
Keyword(s):  
Computed Tomography ◽  
High Resolution ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Clinical Significance ◽  
Lower Lobe ◽  
High Resolution Computed Tomography ◽  
Pleuroparenchymal Fibroelastosis

scholarly journals Erlotinib Treatment in a Case of Lung Adenocarcinoma Mimicking Interstitial Lung Disease

2017 ◽  
Vol 19 (1) ◽  
pp. 51-53
Author(s):  
Senay Yilmaz ◽  
Guntulu Ak ◽  
Muzaffer Metintas
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease

scholarly journals Polymyositis-Dermatomyositis and Interstitial Lung Disease in Pregnant Woman Successfully Treated with Cyclosporine and Tapered Steroid Therapy

2019 ◽  
Vol 2019 ◽  
pp. 1-4 ◽  
Author(s):  
Saito Mayu ◽  
Sakiko Isojima ◽  
Yoko Miura ◽  
Shinichiro Nishimi ◽  
Mika Hatano ◽  
...  
Keyword(s):  
Pregnant Woman ◽  
Interstitial Lung Disease ◽  
Disease Activity ◽  
Lung Disease ◽  
Immunosuppressive Therapy ◽  
Steroid Therapy ◽  
Preterm Births ◽  
Successful Outcome ◽  
First Case ◽  
Immunosuppressant Regimen

Polymyositis-dermatomyositis is extremely rare during pregnancy, and immunosuppressive therapy should be administered after carefully considering the effects on both the mother and fetus. Several reports have associated the disease activity with fetal prognosis, higher rates of eclampsia, preterm births, and fetal deaths. We report our experience with a patient who was diagnosed with polymyositis-dermatomyositis complicated by interstitial lung disease during pregnancy and was treated with a combination-immunosuppressant regimen. To the best of our knowledge, this is the first case wherein cyclosporine was used concomitantly with a steroid for the treatment of polymyositis diagnosed during pregnancy, with successful outcome of childbirth without any complications.

scholarly journals Lung adenocarcinoma presenting as interstitial lung disease

2020 ◽  
Vol 13 (8) ◽  
pp. e235602
Author(s):  
Aditya Mehta ◽  
Anandbir Bath ◽  
Akshaya Gadre ◽  
Mark Schauer
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Adenocarcinoma ◽  
Lung Disease

scholarly journals An SFTPC gene mutation causes childhood interstitial lung disease: first report in the Arab region

JRSM Open ◽  
2020 ◽  
Vol 11 (2) ◽  
pp. 205427041989482
Author(s):  
Mohammed A Alzaid ◽  
Safa Eltahir ◽  
Muhammad Amin Ur Rahman ◽  
Wadha Alotaibi ◽  
Khalid Mobaireek
Keyword(s):  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Protein C ◽  
Surfactant Protein ◽  
Protein C Deficiency ◽  
Arab Region ◽  
Surfactant Protein C ◽  
Computed Tomographic ◽  
First Case ◽  
Childhood Interstitial Lung Disease

Background Surfactant protein C dysfunction is one of the causes of childhood interstitial lung disease but has not previously been reported in Arabian countries. Case presentation A six-year-old girl had presented at the age of eight months old with bronchiolitis followed by a persistent cough, dyspnea and hypoxaemia. She was found to have gastroesophageal reflux disease, but her symptoms did not resolve despite her therapy being optimised. Further tests, including a chest computed tomographic scan, lung biopsy and genetic testing, confirmed a diagnosis of surfactant protein C dysfunction. Conclusion We report the first case in the Arab region of childhood interstitial lung disease caused by surfactant protein C deficiency.

Sign in / Sign up

Export Citation Format

Share Document